GLI1 and breast cancer: The ability of the Wnt pathway to promote GLI1, and potentially tGLI1, activation in combination with the limited efficacy of SMO inhibitors in breast cancer clinical trials provides the rationale for directly targeting tGLI1 as a potential therapeutic modality.